These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 32669958)
1. The prognostic value and potential mechanism of Matrix Metalloproteinases among Prostate Cancer. Geng X; Chen C; Huang Y; Hou J Int J Med Sci; 2020; 17(11):1550-1560. PubMed ID: 32669958 [No Abstract] [Full Text] [Related]
2. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy. Su Q; Liu Z; Chen C; Gao H; Zhu Y; Wang L; Pan M; Liu J; Yang X; Tian J Cancer Med; 2021 Sep; 10(18):6492-6502. PubMed ID: 34453418 [TBL] [Abstract][Full Text] [Related]
3. Fifteen-MiRNA-Based Signature Is a Reliable Prognosis-Predicting Tool for Prostate Cancer Patients. Bian Z; Huang X; Chen Y; Meng J; Feng X; Zhang M; Zhang L; Zhou J; Liang C Int J Med Sci; 2021; 18(1):284-294. PubMed ID: 33390797 [TBL] [Abstract][Full Text] [Related]
4. A pan-cancer perspective of matrix metalloproteases (MMP) gene expression profile and their diagnostic/prognostic potential. Gobin E; Bagwell K; Wagner J; Mysona D; Sandirasegarane S; Smith N; Bai S; Sharma A; Schleifer R; She JX BMC Cancer; 2019 Jun; 19(1):581. PubMed ID: 31200666 [TBL] [Abstract][Full Text] [Related]
5. The novel transcriptomic signature of angiogenesis predicts clinical outcome, tumor microenvironment and treatment response for prostate adenocarcinoma. Gu CY; Dai B; Zhu Y; Lin GW; Wang HK; Ye DW; Qin XJ Mol Med; 2022 Jul; 28(1):78. PubMed ID: 35836112 [TBL] [Abstract][Full Text] [Related]
6. Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer. Cardillo MR; Di Silverio F; Gentile V Anticancer Res; 2006; 26(2A):973-82. PubMed ID: 16619495 [TBL] [Abstract][Full Text] [Related]
7. Identification of a novel matrix metalloproteinases-related prognostic signature in hepatocellular carcinoma. Yuan X; Yang L; Gao J; Mao X; Zhang Y; Yuan W Aging (Albany NY); 2024 May; 16(10):8667-8686. PubMed ID: 38761174 [TBL] [Abstract][Full Text] [Related]
8. A N Mei W; Jia X; Xin S; Liu X; Jin L; Sun X; Zhang JX; Zhang B; Yang G; Chen P; Ye L J Oncol; 2022; 2022():8604216. PubMed ID: 35602299 [TBL] [Abstract][Full Text] [Related]
9. A novel 13 RNA binding proteins (RBPs) signature could predict prostate cancer biochemical recurrence. Xing Q; Liu S; Luan J; Wang Y; Ma L Pathol Res Pract; 2021 Sep; 225():153587. PubMed ID: 34419719 [TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinases MMP-1, MMP-11 and MMP-19 is correlated with the WHO-grading of human malignant gliomas. Stojic J; Hagemann C; Haas S; Herbold C; Kühnel S; Gerngras S; Roggendorf W; Roosen K; Vince GH Neurosci Res; 2008 Jan; 60(1):40-9. PubMed ID: 17980449 [TBL] [Abstract][Full Text] [Related]
11. Identification of the prognostic value of ferroptosis-related gene signature in breast cancer patients. Wang D; Wei G; Ma J; Cheng S; Jia L; Song X; Zhang M; Ju M; Wang L; Zhao L; Xin S BMC Cancer; 2021 May; 21(1):645. PubMed ID: 34059009 [TBL] [Abstract][Full Text] [Related]
12. Identification of Prognostic Biomarkers Associated with Cancer Stem Cell Features in Prostate Adenocarcinoma. Zhang D; Zhang M; Zhang Q; Zhao Z; Nie Y Med Sci Monit; 2020 Jul; 26():e924543. PubMed ID: 32735556 [TBL] [Abstract][Full Text] [Related]
13. Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma. Gu JX; Zhang X; Miao RC; Xiang XH; Fu YN; Zhang JY; Liu C; Qu K World J Gastroenterol; 2019 Jan; 25(2):220-232. PubMed ID: 30670911 [TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566 [TBL] [Abstract][Full Text] [Related]
16. Construction and Validation of a Robust Cancer Stem Cell-Associated Gene Set-Based Signature to Predict Early Biochemical Recurrence in Prostate Cancer. Liu B; Li X; Li J; Jin H; Jia H; Ge X Dis Markers; 2020; 2020():8860788. PubMed ID: 33101546 [TBL] [Abstract][Full Text] [Related]
17. Classification of pyroptosis patterns and construction of a novel prognostic model for prostate cancer based on bulk and single-cell RNA sequencing. Fu J; Li G; Luo R; Lu Z; Wang Y Front Endocrinol (Lausanne); 2022; 13():1003594. PubMed ID: 36105400 [TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling to predict recurrence risk in stage Ι lung adenocarcinoma: Development and validation of a nomogram to clinical management. Ma X; Cheng J; Zhao P; Li L; Tao K; Chen H J Cell Mol Med; 2020 Jul; 24(13):7576-7589. PubMed ID: 32530136 [TBL] [Abstract][Full Text] [Related]
19. Identification of a 6-lncRNA prognostic signature based on microarray re-annotation in gastric cancer. Ma B; Li Y; Ren Y Cancer Med; 2020 Jan; 9(1):335-349. PubMed ID: 31743579 [TBL] [Abstract][Full Text] [Related]
20. Identification and validation of an E2F-related gene signature for predicting recurrence-free survival in human prostate cancer. Yang C; Chen L; Niu Q; Ge Q; Zhang J; Tao J; Zhou J; Liang C Cancer Cell Int; 2022 Dec; 22(1):382. PubMed ID: 36471446 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]